Related Experiment Video
Updated: Sep 29, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Increased serum pro-B-type natriuretic peptide in hematopoietic progenitor cell donors stimulated with G-CSF
Leonard N Chen1, Celina Montemayor-Garcia2, Kamille A West-Mitchell1
1Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Insights
Granulocyte-colony-stimulating factor (G-CSF) mobilization for hematopoietic stem cells (HPCs) commonly elevates pro-B-type natriuretic peptide (proBNP) levels in donors. This temporary increase is not linked to heart dysfunction and warrants further investigation into risk factors.
Area of Science:
- Hematology
- Cardiology
- Biochemistry
Background:
- Granulocyte-colony-stimulating factor (G-CSF) is used to mobilize hematopoietic stem cells (HPCs) for donation.
- Mobilization can cause adverse effects in donors.
- Pro-B-type natriuretic peptide (proBNP) is a biomarker for heart failure.
Purpose of the Study:
- To investigate the prevalence of elevated serum proBNP levels in HPC donors after G-CSF mobilization.
- To identify potential risk factors associated with proBNP elevation.
Main Methods:
- A case series of 18 healthy HPC donors undergoing G-CSF mobilization (10 mcg/kg/day for 5 days).
- Serum proBNP levels measured pre-mobilization, post-mobilization, and post-apheresis.
- Analysis of apheresis collection parameters and other laboratory results.
Main Results:
- The majority of donors (86.7%) showed increased serum proBNP post-G-CSF.
- Seven donors had proBNP levels exceeding the upper normal limit (124 pg/ml).
- Donors with normal proBNP were younger, predominantly male, and had smaller processed blood volumes.
Conclusions:
- Elevated serum proBNP is a common, previously undescribed adverse reaction in HPC donors receiving G-CSF.
- Temporary proBNP elevation is not associated with cardiac ventricular dysfunction.
- Further research is needed to identify risk factors for significant proBNP elevation.
Abstract:
Hematopoietic stem cells (HPCs) donors mobilized by granulocyte-colony-stimulating factor (G-CSF) can develop various signs and symptoms. proBNP (pro-B-type natriuretic peptide) is a serum marker of heart failure. A donor who developed severe adverse reactions after G-CSF mobilization was found to have high serum proBNP levels. We followed additional donors who received identical mobilization regimen to investigate the prevalence of this phenomenon. Eighteen healthy donors underwent a mobilization regimen of 10 microg/Kg G-CSF daily for 5 days prior to allogeneic HPC collection using Spectra Optia between January 2016 and February 2017 were included in this study. Serum proBNP levels were measured before and after G-CSF stimulation and immediately after apheresis. Apheresis collection parameters and other laboratory results were also reviewed. The majority of donors (86.7%) had post-G-CSF elevation of serum proBNP. Seven of those had elevated proBNP above upper normal range (124 pg/ml). The subgroup of donors with normal proBNP is younger (median age of 37 vs 42 years), with majority being male (90.9% vs 28.6%) and with smaller processed blood volume (2.2 vs 3 × total blood volume). This case series demonstrates an increase of serum proBNP can be common in HPC donors stimulated with 5 days of 10 mcg/kg G-CSF. This is an adverse reaction that has not been described before. The temporary elevation of proBNP in these donors is not associated with ventricular dysfunction of the heart. The risk factors for marked elevation of proBNP post-G-CSF should be further investigated.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Hematopoiesis

